PARP as a Therapeutic Target
Crc Press Inc (Verlag)
978-0-8493-0073-8 (ISBN)
- Titel ist leider vergriffen;
keine Neuauflage - Artikel merken
Recent research in cell death mechanisms has rekindled interest in PARP's (Poly (ADP-Ribose) Polymerase) intriguing role in necrosis and apoptosis. While the details of how PARP1 functions are still being elucidated, it has tremendous potential as a promising drug target. PARP inhibitors' dual actions of preventing cell death and abating inflammation have demonstrated remarkable acute effects in animal models of various diseases.
PARP as a Therapeutic Target covers the clinical aspects of this up-and-coming drug that counteracts the damage done by free radicals. Leading international experts currently working on ways to apply it share their views of recent developments and future directions of PARP research. They discuss its therapeutic potential in various disease conditions, such as ischemia, diabetes, cancer, arthritis, inflammatory bowel disease, and septic shock.
The intensified PARP drug development effort has raised expectations for possible clinical trials in the near future to establish the tolerance of PARP inhibitors in healthy humans, its efficacy in treating patients with different diseases, and the long term effect of PARP inhibition. PARP as a Therapeutic Target provides a comprehensive understanding of how PARP works to aid in the better design of its inhibitors for therapeutic purposes.
Jei Zhang
PARP in the Nervous System. Role of PARP1 in Neurologic Disorders. The Role of PARP on Safeguarding Genomic Integrity. Functional Testing of Human PARP in Proliferation, Endotoxic Shock and Radiosensitivity. PARP Inhibitors as Neuroprotective Agents for Brain Injury. PARP-Inhibitors and Cardioprotection. Neuroprotection of the Retina with 3-Aminobenzamide, a PARP Inhibitor. PARP Inhibitors and Acute Renal Failure. Role of PARP Activation in the Pathogenesis of Shock and Inflammation. Clinical Development of the Nicotinamides and Benzamides Involving PARP as a Molecular Target. Chemoprotective Effect of a Novel PARP Inhibitor. Beneficial Effect of GPI 6150 Treatment in Multiple Animal Models of Diseases. Protective Effect of PARP Inhibition on UV Light Induced Skin Damage. Role of PARP in the Islet Injury and Vascular Complications Associated with Diabetes Mellitus. ADP-Ribose Polymer Metabolism.
Erscheint lt. Verlag | 6.3.2002 |
---|---|
Reihe/Serie | Handbooks in Pharmacology and Toxicology |
Co-Autor | Prabal K. Chatterjee, Sandor Bernath, Anders Olsson, Tim T. Lam |
Zusatzinfo | 7 Halftones, black and white; 65 Illustrations, black and white |
Verlagsort | Bosa Roca |
Sprache | englisch |
Maße | 156 x 234 mm |
Gewicht | 702 g |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
Naturwissenschaften ► Biologie ► Zellbiologie | |
Technik | |
ISBN-10 | 0-8493-0073-8 / 0849300738 |
ISBN-13 | 978-0-8493-0073-8 / 9780849300738 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
aus dem Bereich